To prevent, treat, and cure tuberculosis globally.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill reauthorizes Section 104B of the Foreign Assistance Act, which governs U.S. global tuberculosis programs. It aligns U.S. efforts with WHO goals to reduce TB deaths by 95% and TB incidence by 90% by 2035, and supports treatment of 40 million TB patients.
Who Benefits and How
TB patients globally gain expanded access to diagnosis and treatment. Countries with high TB burden receive U.S. assistance. Global health security improves by reducing a platform for future pandemics.
Who Bears the Burden and How
U.S. foreign assistance budget funds the program.
Key Provisions
- Supports WHO End TB Strategy goals (95% death reduction, 90% incidence reduction by 2035)
- Targets treating 40M people including 3.5M children and 1.5M drug-resistant cases
- Supports prevention for 30M people with latent TB
- Emphasizes innovative technologies and sustainable commodity procurement
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Reauthorizes and strengthens U.S. foreign assistance programs to combat tuberculosis globally, aligning with WHO End TB Strategy goals for 2035.
Who Benefits
- TB patients globally
- High-burden countries
- Global health security
Who Bears Costs
- U.S. foreign assistance budget
Key Policy Areas
Global Health, Foreign Assistance, Infectious Disease
Primary Purpose
Reauthorizes and strengthens U.S. foreign assistance programs to combat tuberculosis globally, aligning with WHO End TB Strategy goals for 2035.
Policy Domains
Legislative Strategy
"Align U.S. TB programs with international goals and expand treatment targets"
Sponsors
Legislative Progress
Passed SenateMr. Menendez (for himself and Mr. Young) introduced the following …
Passed Senate (inferred from es version)
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
USAID TB programs, USAID and global health programs
Global health NGOs working on TB, Global health organizations
Pharmaceutical companies developing TB treatments, TB diagnostics and pharmaceutical companies
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology